Finoriq research workspace
Aktis Oncology, Inc. (AKTS) Institutional Holdings & 13F Ownership
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development. Review AKTS institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Company
- Aktis Oncology, Inc. (AKTS)
- Ticker
- AKTS
- Market Cap
- $1.3B
- Latest Price
- $23.81
- Industry
- Biotech & Pharma
Aktis Oncology, Inc. (AKTS) Top Institutional Holders
Top current 13F holders indexed for Aktis Oncology, Inc. (AKTS). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | George SorosCIK 0001029160 | $1.8M | 0.02% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.